News · Vaccines
Japan approves a prefilled syringe for GSK's Shingrix

Photo: Harrison Cohen / Unsplash
Japan's Ministry of Health, Labour and Welfare (MHLW) has approved a prefilled syringe presentation of Shingrix, GSK's recombinant zoster vaccine against shingles. GSK announced the approval from London on September 10, 2026. Until now the vaccine came in two vials, a freeze-dried antigen and a liquid adjuvant, which staff combined by hand just before each shot. The new syringe is ready to use.
GSK says the approval rests on data showing technical comparability with the existing two-vial presentation. The indication and dosing stay the same. GSK launched the syringe in the US in February 2026 and is introducing it across Europe during the year. Neither GSK nor PharmaTimes, which reported the approval, said when the syringe will reach clinics in Japan. GSK's release also does not say whether Japan handled the syringe as a partial change to the existing approval or as an approval of its own.
The two-vial format puts work on the clinic. Someone draws up the adjuvant, mixes it with the antigen and withdraws the dose. Each step is short. At a busy vaccination site the minutes add up, and every extra step is another chance for a mix-up. A prefilled syringe moves that step back to the manufacturer.
It moves the quality questions with it. The vaccine now sits against the syringe barrel and plunger for its whole shelf life, so aggregation in the syringe has to be assessed. Factors that come from the container, such as silicone oil and tungsten residues, start to matter. How easily the dose goes in depends on the combination of viscosity, inner diameter and the force on the plunger. Filling becomes an aseptic operation, and the syringe also has to be evaluated as a device. When an existing product changes its presentation, the company must show that the new form is equivalent to the old one.
GSK presents the change as a convenience for healthcare professionals. For suppliers of syringes, components and fill-finish capacity, it reads more as a question of how a vaccine and its container behave together over years of storage.
Sources
- GSK's Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Japan. GSK, Sep 2026.
- Japan approves prefilled syringe for GSK's shingles vaccine. PharmaTimes, Sep 2026.